Journal article
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study*
Abstract
Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage …
Authors
Skamene T; Crump M; Savage KJ; Reiman T; Kuruvilla J; Good D; LeBrun D; Meyer RM; Sehn LH; Soulières D
Journal
Leukemia & Lymphoma, Vol. 58, No. 10, pp. 2319–2327
Publisher
Taylor & Francis
Publication Date
October 3, 2017
DOI
10.1080/10428194.2017.1312379
ISSN
1042-8194